An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin's Lymphoma.

Trial Profile

An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Gemcitabine; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Jan 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top